Zimmer Biomet (NYSE:ZBH) Insider Sang Yi Sells 5,000 Shares

03 Jun 2026, 05:55 by Mitch Edgeman · The Markets Daily

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.87 during trading hours on Tuesday, reaching $83.70. The company’s stock had a trading volume of 2,704,138 shares, compared to its average volume of 2,133,308. The company’s 50 day simple moving average is $87.82 and its 200 day simple moving average is $90.61. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The stock has a market cap of $16.19 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 1.90 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period last year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Institutional Trading of Zimmer Biomet

A number of institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new stake in Zimmer Biomet during the second quarter worth $232,000. United Bank boosted its stake in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares in the last quarter. Federated Hermes Inc. boosted its stake in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 1,202 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ZBH shares. UBS Group reissued a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Citizens Jmp decreased their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a report on Wednesday, April 29th. Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. Finally, Citigroup decreased their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $102.70.

Read Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.